This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | MicrobiomeTrials
← Back to trials NCT07349641
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-06Est. Completion: 2028-12-31
Enrollment target: 55 participantsLocations Northwestern University, Chicago, Illinois, United States Lyndon Baines Johnson General Hospital, Houston, Texas, United States UT MD Anderson Cancer Center, Houston, Texas, United States Other microbiome trials you might be interested in Endometrial Neoplasms Endometrial Cancer Atypical Endometrial Hyperplasia Progestin Resistance
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standar…
Beijing, China Est. completion Sep 2027
Endometrial Hyperplasia
Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).
Endometrial hy…
Birmingham, United States Completed Jun 17, 2026